Equities

Ziccum AB

Ziccum AB

Actions
  • Price (SEK)5.82
  • Today's Change-0.300 / -4.90%
  • Shares traded11.92k
  • 1 Year change+25.96%
  • Beta1.1969
Data delayed at least 15 minutes, as of May 08 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ziccum AB is a Sweden-based pharmaceutical company that is mainly engaged in developing vaccines. Ziccum develops new thermostable versions of vaccines and biologics for licensing to vaccine suppliers, developers, manufacturers and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yield and low waste. These robust, thermostable dry powders can be stored and transported worldwide without the need for a cold chain or freezing. The company conducts its business by entering into strategic collaborations with major pharmaceutical companies and offering licenses to the Company's patented technology.

  • Revenue in SEK (TTM)3.75m
  • Net income in SEK-21.41m
  • Incorporated2018
  • Employees8.00
  • Location
    Ziccum ABScheelevagen 15LUND 223 63SwedenSWE
  • Phone+46 84429586
  • Websitehttps://ziccum.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Combigene AB5.54m-35.67m73.26m8.00--0.6291--13.21-1.80-1.800.285.880.0398--2.63693,015.00-25.58-13.00-26.56-14.58-----643.32-58.77----0.00---79.23268.58-479.27---24.02--
Chosa Oncology AB73.00k-23.94m73.63m----4.23--1,008.66-0.3524-0.35240.00130.26840.003--0.013---96.68-51.96-178.66-61.92-----32,798.63-708.47---97.97-----98.21--28.33------
ExpreS2ion Biotech Holding AB8.80m-95.99m76.28m28.00--1.25--8.67-2.12-2.120.18951.190.0832--9.91---90.72-64.80-113.72-77.46-109.74-1.94-1,090.91-532.25----0.0045--43.07-0.156119.07--19.90--
Immunovia AB (publ)1.21m-260.73m81.70m11.00--1.87--67.41-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
Dextech Medical AB0.00-4.53m90.58m1.00--2.93-----0.2449-0.24490.001.67-----------28.96---29.94------------0.00------12.89--0.412--
Wntresearch AB0.00-32.47m93.53m2.00--1.77-----0.1108-0.11080.000.06090.00----0.00-134.85-100.71-166.68-123.59------------0.00-------5.65------
Ziccum AB3.75m-21.41m94.08m8.00--9.88--25.11-1.54-1.540.27010.61910.1553--2.01468,375.00-88.74-68.51-109.73-76.47-----571.44-2,598.03----0.0908----75.2025.62---13.45--
Sprint Bioscience AB50.49m-441.00k94.68m28.00--3.4113,525.151.88-0.0064-0.00640.72320.39781.01--7.581,803,036.00-0.8838-71.22-1.58-113.7182.7762.75-0.8735-110.22----0.00--60,725.3022.9999.27---26.02--
Biosergen AB0.00-27.04m94.92m3.00--8.19-----0.4007-0.40070.000.04180.00----0.00-131.31---217.09----------------------32.25------
AroCell AB (publ)43.04m-59.30m100.21m----0.6123--2.33-0.2574-0.25740.18680.71040.20956.686.52---28.86-29.25-30.70-31.37-4.38-9.85-137.78-231.195.25--0.00--16.37122.92-0.5494------
Bioextrax AB publ2.06m-21.51m101.64m----4.23--49.41-0.8026-0.80260.07690.69680.0681--124.67---71.18-86.39-82.24-110.8434.95---1,045.55-2,119.90--------420.5124.40-15.21--56.86--
Opticept Technologies AB9.15m-80.36m103.40m29.00--0.2268--11.31-2.62-2.620.298110.800.0213-0.06382.37315,344.80-18.69-41.76-21.19-46.21125.8862.65-879.63-882.410.6163-14.160.0566---12.9049.1719.80--45.22--
Toleranzia AB0.00-7.46m106.42m----0.6932-----0.0597-0.05970.000.7790.00-------5.21-7.45-5.43-7.78------------0.0055------11.79--63.90--
Annexin Pharmaceuticals AB (publ)0.00-46.41m106.75m4.00--16.82-----0.1887-0.18870.000.01830.00----0.00-256.08-125.42-351.79-151.33------------0.00-------8.17------
Odi Pharma AB (publ)818.38k-3.97m110.35m----54.19--134.83-0.2608-0.26080.05380.13380.10841.226.98---52.58---95.24---53.07---484.96--1.32-14.100.00---55.44--4.67------
Bio-Works Technologies AB43.90m-56.82m114.60m38.00--2.60--2.61-1.58-1.581.221.130.5711.825.831,155,158.00-73.91-49.14-101.72-57.9061.1069.88-129.44-168.302.79--0.00--6.2346.24-26.41--1.95--
Data as of May 08 2024. Currency figures normalised to Ziccum AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.